Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.4900 per share.
- Transaction Volume: 363.463 shares.
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Mr. R G Connor, President of Global Manufacturing & Supply. This change resulted from the re-investment of dividends paid on July 14, 2016, under the Company's Deferred Investment Award Programme. No material changes to the company's overall financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of a PDMR transaction.
Investor Verification Points
- Verify the impact of the Deferred Investment Award Programme on executive compensation structures.
- Confirm the share price of £16.4900 against market data for July 14, 2016.
- Note that this filing contains no operational or financial performance data for the quarter or year.